Title : Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.

Pub. Date : 2010 Nov

PMID : 20878066






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent. Paclitaxel tumor protein p53 Homo sapiens
2 In this report, using a cell line with knock-down p53 expression through siRNA, we found that amifostine enhancement of paclitaxel"s anticancer effect is p53 status-dependent. Paclitaxel tumor protein p53 Homo sapiens
3 In this report, using a cell line with knock-down p53 expression through siRNA, we found that amifostine enhancement of paclitaxel"s anticancer effect is p53 status-dependent. Paclitaxel tumor protein p53 Homo sapiens
4 Sensitivity to the therapeutic effect of paclitaxel in combination with amifostine was dependent upon the status of p53. Paclitaxel tumor protein p53 Homo sapiens
5 A tumor with a nonsense TP53 mutation showed increased therapeutic response to paclitaxel and amifostine as measured by tumor weight compared to a tumor with wild- type TP53. Paclitaxel tumor protein p53 Homo sapiens
6 Our study provides a rationale for a clinical trial of combined paclitaxel and amifostine in endometrial cancer patients whose tumors harbor TP53 mutations. Paclitaxel tumor protein p53 Homo sapiens